Replies to post #303039 on Avid Bioservices Inc (CDMO)

[Bluerinse]

Well said ... I have a huge issue with what was said about bavi .. brutal actually ... I hope someone else comes to the table as their is no reason to think the existing team has what it takes
Imo

[north40000]

Perhaps some questions will be asked tomorrow re status of #s 11 and 20.

https://clinicaltrials.gov/ct2/results?cond=&term=bavituximab&cntry1=&state1=&SearchAll=Search+all+studies&recrs=#wrapper

[keep_trying]

PD, well said. My take on recent action can be summarized in a good news bad news context.
The good news is that a pharma appears ready to show their hand to acquire PPHM's technology rights. The bad new is that Ronin has emerged saying PPHM value equals only Avid value such that Ronin is riding with company control demands, in behind the now $14 price target by analysts doing valuation based on projected Avid sales.

I perceive what is in play now as running parallels to the study group dosing mislabeling trial sabatoge during the Phase 3 Bavi studies. I observe the manipulative nature of the Ronin proxy statements seem designed to end run around a managment team that values the PPHM tech at more than the pharma wants to pay whereas Ronin is writing in their proxy how they consider the tech value is at zero.

PPHM is set to announce a shift to net positive earnings this fiscal year, per announced plans. Anyway valuation should bring a $14 pps plus PPHM still has its technology rights intact for negotiations with Pharma. We don't need a Ronin BOD change to extract Avid value out of PPHM. The build up of Avid valuation is already a work in progress under current BOD leadership plus PPHM is preserving tech value for prospective tech rights agreements

Of courss, all IMO.
KT